BIOSANTE PHARMACEUTICALS COMMENTS ON NEW DATA FROM WOMEN'S HEALTH INITIATIVE STUDY

BioSante Pharmaceuticals, Inc. today offered comment on new data from the Women's Health Initiative (WHI) study, published in the April 12, 2006 issue of the Journal of the American Medical Association (JAMA), demonstrating that estrogen-alone therapy did not increase breast cancer incidence in postmenopausal women after an average of 7.1 years.
Genetic Engineering News